Bupropion HCl | CAS#31677-93-7

Bupropion HCl
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317359

CAS#: 31677-93-7 (HCl)

Description: Bupropion, also known as amfebutamone and BW 323, is a norepinephrine–dopamine reuptake inhibitor (NDRI) and a nicotinic receptor antagonist. However, its effects on dopamine are weak and clinical significance is contentious. Chemically, bupropion is an aminoketone that belongs to the class of substituted cathinones and more generally that of substituted amphetamines and substituted phenethylamines.

Chemical Structure

Bupropion HCl

CAS# 31677-93-7 (HCl)

Instruction

Theoretical Analysis

MedKoo Cat#: 317359
Name: Bupropion HCl
CAS#: 31677-93-7 (HCl)
Chemical Formula: C13H19Cl2NO
Exact Mass: 239.11
Molecular Weight: 276.201
Elemental Analysis: C, 56.53; H, 6.93; Cl, 25.67; N, 5.07; O, 5.79

Price and Availability

Size	Price	Availability
1g	USD 250	2 Weeks
10g	USD 450	2 Weeks
25g	USD 950	2 Weeks
50g	USD 1650	2 Weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: Bupropion HCl; amfebutamone; Bupropion, Wellbutrin, Zyban; BW 323; BW-323; BW323. NSC 315851; NSC-315851; NSC315851;

IUPAC/Chemical Name: 2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one hydrochloride

InChi Key: HEYVINCGKDONRU-UHFFFAOYSA-N

InChi Code: InChI=1S/C13H18ClNO.ClH/c1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10;/h5-9,15H,1-4H3;1H

SMILES Code: CC(NC(C)(C)C)C(C1=CC=CC(Cl)=C1)=O.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 276.20 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. Bupropion. 2024 Jan 15. PMID: 30000243.

2: Bakouni H, Sharafi H, Bahremand A, Drouin S, Ziegler D, Bach P, Le Foll B, Schütz CG, Tardelli V, Ezard N, Siefried K, Jutras-Aswad D. Bupropion for treatment of amphetamine-type stimulant use disorder: A systematic review and meta-analysis of placebo-controlled randomized clinical trials. Drug Alcohol Depend. 2023 Dec 1;253:111018. doi: 10.1016/j.drugalcdep.2023.111018. Epub 2023 Nov 4. PMID: 37979478.

3: Jiang Q, Velu P, Sohouli MH, Ziamanesh F, Shojaie S, Fatahi S, Li Q. The effects of bupropion alone and combined with naltrexone on blood pressure and CRP concentration: A systematic review and meta-regression analysis of randomized controlled trials. Eur J Clin Invest. 2024 Mar;54(3):e14118. doi: 10.1111/eci.14118. Epub 2023 Nov 4. PMID: 37924302.

4: McCarthy B, Bunn H, Santalucia M, Wilmouth C, Muzyk A, Smith CM. Dextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder. Clin Psychopharmacol Neurosci. 2023 Nov 30;21(4):609-616. doi: 10.9758/cpn.23.1081. Epub 2023 Jul 17. PMID: 37859435; PMCID: PMC10591164.

5: Patel AR, Panchal JR, Desai CK. Efficacy of varenicline versus bupropion for smoking cessation: A systematic review and meta-analysis of randomized controlled trials. Indian J Psychiatry. 2023 May;65(5):526-533. doi: 10.4103/indianjpsychiatry.indianjpsychiatry_218_22. Epub 2023 May 15. PMID: 37397838; PMCID: PMC10309263.

6: Mother To Baby | Fact Sheets [Internet]. Brentwood (TN): Organization of Teratology Information Specialists (OTIS); 1994–. Bupropion. 2023 Jul. PMID: 35951874.

7: Aikoye S, Basiru TO, Nwoye I, Adereti I, Asuquo S, Ezeokoli A, Hardy J, Umudi O. A Systematic Review of Abuse or Overprescription of Bupropion in American Prisons and a Synthesis of Case Reports on Bupropion Abuse in American Prison and Non-prison Systems. Cureus. 2023 Mar 15;15(3):e36189. doi: 10.7759/cureus.36189. PMID: 37065297; PMCID: PMC10104426.

8: Keam SJ. Dextromethorphan/Bupropion: First Approval. CNS Drugs. 2022 Nov;36(11):1229-1238. doi: 10.1007/s40263-022-00968-4. PMID: 36301443.

9: Oravecz R, Stuhec M. Bupropion XL unapproved use in the prisons: Two cases focused on the bupropion pharmacology. Psychiatr Hung. 2022;37(3):246-249. PMID: 36264167.

10: Dahlberg S, Chang ET, Weiss SR, Dopart P, Gould E, Ritchey ME. Use of Contrave, Naltrexone with Bupropion, Bupropion, or Naltrexone and Major Adverse Cardiovascular Events: A Systematic Literature Review. Diabetes Metab Syndr Obes. 2022 Sep 29;15:3049-3067. doi: 10.2147/DMSO.S381652. PMID: 36200062; PMCID: PMC9529009.

11: Correa-Morales JE, Cuellar-Valencia L, Mantilla-Manosalva N, Quintero-Muñoz E, Iriarte-Aristizábal MF, Giraldo-Moreno S, Rodríguez-Campos LF. Cancer and Non-cancer Fatigue Treated With Bupropion: A Systematic Review. J Pain Symptom Manage. 2023 Jan;65(1):e21-e28. doi: 10.1016/j.jpainsymman.2022.09.011. Epub 2022 Oct 2. PMID: 36198335.

12: El Hayek SA, Shatila MA, Adnan JA, Geagea LE, Kobeissy F, Talih FR. Is there a therapeutic potential in combining bupropion and naltrexone in schizophrenia? Expert Rev Neurother. 2022 Sep;22(9):737-749. doi: 10.1080/14737175.2022.2124369. Epub 2022 Sep 14. PMID: 36093756.

13: Vismara M, Benatti B, Nicolini G, Cova I, Monfrini E, Di Fonzo A, Fetoni V, Viganò CA, Priori A, Dell'Osso B. Clinical uses of Bupropion in patients with Parkinson's disease and comorbid depressive or neuropsychiatric symptoms: a scoping review. BMC Neurol. 2022 May 5;22(1):169. doi: 10.1186/s12883-022-02668-4. PMID: 35513785; PMCID: PMC9069850.

14: Guo K, Wang S, Shang X, E F, Hou L, Li J, Li Y, Yang K, Li X. The effect of Varenicline and Bupropion on smoking cessation: A network meta-analysis of 20 randomized controlled trials. Addict Behav. 2022 Aug;131:107329. doi: 10.1016/j.addbeh.2022.107329. Epub 2022 Apr 5. PMID: 35397262.

15: Rianprakaisang TN, Prather CT, Lin AL, Murray BP, Hendrickson RG; Toxicology Investigators Consortium (ToxIC). Factors associated with seizure development after bupropion overdose: a review of the toxicology investigators consortium. Clin Toxicol (Phila). 2021 Dec;59(12):1234-1238. doi: 10.1080/15563650.2021.1913180. Epub 2021 Apr 21. PMID: 33878992.

16: Sposito AC, Bonilha I, Luchiari B, Benchimol A, Hohl A, Moura F, Cercato C, Geloneze B, Nadruz W, Aguilar-Salinas C, Carvalho LSF. Cardiovascular safety of naltrexone and bupropion therapy: Systematic review and meta-analyses. Obes Rev. 2021 Jun;22(6):e13224. doi: 10.1111/obr.13224. Epub 2021 Apr 12. PMID: 33847068.

17: MacDonald E, Horton J. Bupropion for Major Depressive Disorder or Persistent Depressive Disorder (Dysthymia) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2021 Apr. PMID: 34260168.

18: Tran K, McGill SC, Horton J. Bupropion for Treatment-Resistant Depression [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2021 Apr. PMID: 34260167.

19: Lee WK, Au Yeung KL, Lam HB, Wong CK, Wong TC, Fu CK, Sham SK, Au MK, Lam TC, Ki-Yan Mak D. Consensus statements on the clinical understanding and use of bupropion in Hong Kong. CNS Neurosci Ther. 2021 Mar;27 Suppl 1(Suppl 1):20-24. doi: 10.1111/cns.13376. PMID: 33555615; PMCID: PMC7869927.

20: González-Urbieta I, Jafferany M, Torales J. Bupropion in dermatology: A brief update. Dermatol Ther. 2021 Jan;34(1):e14303. doi: 10.1111/dth.14303. Epub 2020 Sep 22. PMID: 32926554.

Your view history

Bupropion HCl featured